Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Shares Outstanding (Weighted Average) (2016 - 2025)

Cytokinetics (CYTK) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $120103.0 as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) changed N/A to $120103.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $120103.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $120103.0 for FY2025, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $120103.0 at Cytokinetics, roughly flat from $119982.0 in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $120103.0 in Q4 2025, with the low at $28306.0 in Q4 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $89579.7, with a median of $95312.5 recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) soared 354.92% in 2021, then plummeted 63.18% in 2022.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $76886.0 in 2021, then tumbled by 63.18% to $28306.0 in 2022, then skyrocketed by 241.0% to $96524.0 in 2023, then rose by 13.89% to $109932.0 in 2024, then rose by 9.25% to $120103.0 in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $120103.0, $119982.0, and $118979.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.